Clinuvel just announced today that the FDA has agreed to discuss and implement the North American development program for SCENESSE (afamelanotide 16mg) for the pigment loss disorder vitiligo. In a study done in the United States, it was shown that significant recovery of pigmentation was observed in patients with darker skin complexion (Fitzpatrick skin types IV-VI). This is wonderful news, and something we have all been waiting for since the medicine’s approval by the FDA in October 2019 to increase pain-free light exposure in adult patients with the rare metabolic disorder erythropoietic protoporphyria (EPP). April 29 is the date set for the discussion, and I will update you here as news becomes available.
More News on Scenesse in Vitiligo
Love this Post? Spread the World